Telpegfilgrastim to prevent low white blood cells in solid tumor patients
Treatments studied
Part of Blood & lymphatic, Cancer clinical trials.
This trial tests a once-per-cycle injection (Telpegfilgrastim) to help keep your white blood cell count from dropping dangerously low during chemotherapy. It is for people with solid tumors who are at increased risk for neutropenia (low infection-fighting cells).
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are between 18 and 69 years old.
- You weigh at least 45 kg (about 99 pounds).
- You have been diagnosed with a malignant solid tumor (a confirmed cancer that is not a blood cancer).
- You are receiving chemotherapy every 3 weeks that is considered high-risk or moderately risky for causing a fever with low white blood cells.
- Your performance status is 70 or higher on the Karnofsky scale, meaning you can care for yourself and do daily activities.
- Your white blood cell count and neutrophil count are normal before starting chemotherapy.
- You are expected to live at least 6 more months.
- You are not pregnant or breastfeeding.
- You have not used a similar long-acting white blood cell booster (PEG-rhG-CSF) in the last 4 weeks.
- Your liver and kidney function are within acceptable limits.
- You are not allergic to G-CSF drugs or other biologic medications.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial compares two drugs (Telpegfilgrastim and Filgrastim) to help prevent dangerously low white blood cell counts after chemotherapy in children and young adults with solid tumors. It's for patients who have already had this problem in a previous chemo round.
This trial tests a medication that aims to reduce the risk of dangerously low white blood cell counts (neutropenia) after chemotherapy combined with immunotherapy for certain advanced lung or esophageal cancers. It may help prevent infections and other complications, making treatment safer.
This study tests a new medicine called Telpegfilgrastim to help prevent fever from low white blood cell counts in children (14–17) with certain cancers who are getting strong chemotherapy. It aims to see if the medicine is safe and works well.
This study looks at whether a common side effect (bone pain) from a medicine that boosts white blood cells (called G-CSF) is related to the number of neutrophils (a type of white blood cell) in your blood. If you join, you will receive the medicine as part of your normal chemotherapy routine, and the researchers will track your blood counts and any bone pain you experience.
This Phase 2 study tests mecapegfilgrastim with chemotherapy to help your body collect enough peripheral blood stem cells for an autologous transplant (using your own cells). It’s for people with multiple myeloma or certain lymphomas who have already had some response to treatment.
This study tests a drug (me capegfilgrastim) given as a shot to help prevent a dangerous drop in white blood cells and fever during chemotherapy. It is for people with cancer who are at high risk for this side effect.
Hear when a new Chemotherapy-induced Neutropenia trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.